Table 2.
Encapsulation efficiency and drug-loading capacity of β-Sit-PLGA and β-Sit-PEG-PLA nanoparticles. Results represent mean ± SD (n = 3).
| Formulation | Weight of β-sitosterol Used for Formulation | |||||
|---|---|---|---|---|---|---|
| 2 mg/mL | 4 mg/mL | |||||
| EE (%) | EDL % | ADL (%) | EE (%) | EDL % | ADL (%) | |
| β-Sit-PLGA-EtAC | 62.89 ± 4.66 | 4.76 | 3.00 ± 0.22 | 48.41 ± 23.82 | 9.09 | 4.4 ± 2.17 |
| β-Sit-PLGA-DCM | 85.13 ± 6.35 | 4.76 | 4.05 ± 0.30 | 88.48 ± 0.01 a | 9.09 | 8.04 ± 0.01 a |
| β-Sit-PEG-PLA (R45) | 51.83 ± 19.72 | 4.76 | 2.47 ± 0.94 | 71.02 ± 22.48 | 9.09 | 6.46 ± 2.04 |
| β-Sit-PEG-PLA (R25) | 34.84 ± 1.71 | 4.76 | 1.67 ± 0.08 | 66.85 ± 8.13 | 9.09 | 6.08 ± 0.74 |
EE = encapsulation efficiency, EDL = expected drug loading, ADL = actual drug loading. a Result represents mean ± SD (n = 2).